Frequently Asked Questions (FAQs)
Baricitinib is authorized for use under an Emergency Use Authorization (EUA) for treatment of COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Baricitinib has not been approved for the treatment of COVID-19, but has been authorized for emergency use by the FDA.
Baricitinib is authorized under an EUA only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of baricitinib under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.
- The FDA clarified that individuals determined as being appropriate for acute inpatient hospitalization and who are admitted or transferred to an alternate care site (ACS) that is capable of providing acute care that is comparable to general inpatient hospital care are within the terms and conditions of the Letter of Authorization. An ACS is intended to have additional hospital surge capacity and capabilities for communities overwhelmed by patients with COVID-19.
There is limited information regarding use of baricitinib in patients with COVID-19 and any of the following clinical findings: absolute neutrophil count (ANC) <1000 cells/mm3, absolute lymphocyte count (ALC) <200 cells/mm3, and hemoglobin <8 g/dL.
Evaluate baseline eGFR, liver enzymes, and complete blood count to determine treatment suitability and dose. Monitor closely patients with abnormal baseline and post-baseline laboratory values.
See Table 1 for dosage adjustments for patients with laboratory abnormalities.
Baricitinib is not recommended for:
- Patients who are on dialysis, have ESRD (eGFR <15 mL/min/1.73 m2), or have acute kidney injury
- Patients with known active tuberculosis
- In hospitalized patients with COVID-19, prophylaxis for VTE is recommended unless contraindicated. If clinical features of deep vein thrombosis/pulmonary embolism occur, patients should be evaluated promptly and treated appropriately.
The efficacy and safety of baricitinib were assessed in two phase 3, randomized, double-blind, placebo-controlled clinical trials:
- ACTT‑2, which evaluated the combination of baricitinib 4 mg and remdesivir compared to placebo and remdesivir.
- COV-BARRIER, which evaluated baricitinib 4 mg compared to placebo. Patients could remain on background therapy, as defined per local guidelines.
In ACTT-2, all patients received standard supportive care at the trial site hospital. If a hospital had a written policy for COVID-19 treatments, patients could receive those treatments. In the absence of a written policy, other experimental treatment and off-label use of marketed medications intended as specific treatment for COVID-19 were prohibited. This included corticosteroids, which were permitted only for standard indications such as adrenal insufficiency, asthma exacerbation, laryngeal edema, septic shock, and acute respiratory distress syndrome. There were 223 patients who received corticosteroids for clinical indications during the trial.
In COV-BARRIER, patients could remain on background standard of care, as defined per local guidelines, including antimalarials, antivirals such as remdesivir, corticosteroids, and/or azithromycin. The most frequently used therapies were corticosteroids (79% of patients, mostly dexamethasone) and remdesivir (19% of patients).
- No, baricitinib is distributed via Lilly's Authorized Distributors of Record for the EUA to inpatient pharmacies. Lilly remains confident in being able to meet the supply needs of patients under the EUA, as well as for the existing approved indication.
- For information related to participation in Lilly’s clinical trials, please call 1-877-285-4559 or email covid19potentialsite@lilly.com.
- Patients should visit Lilly Trial Guide for information regarding eligibility for ongoing trials.
Please see more information on Lilly's Global COVID-19 Response here.